Expression, localization, and phosphorylation of Akt1 in benign and malignant thyroid lesions

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• The serine/threonine protein kinase Akt is a crucial signaling molecule in the phosphatidyl inositol 3-kinase pathway.
• Akt is frequently overactivated in human cancers, indicating its role in tumorigenesis.
• Three Akt isoforms (Akt1, Akt2, Akt3) exist with distinct functions and distributions.

Purpose of the Study:

• To investigate differences in Akt1 expression, phosphorylation, and cellular localization between benign and malignant human thyroid lesions.
• To assess the potential role of Akt1 as a biomarker in thyroid cancer.

Main Methods:

• Isolation of nuclear and cytoplasmic fractions from thyroid tissue samples.
• Western blot analysis to detect Akt1 expression and localization.
• ELISA for quantifying Akt1 expression.
• Immunoprecipitation and Western blot with anti-phospho-Akt antibodies to assess Akt1 phosphorylation.

Main Results:

• Akt1 expression was significantly higher in the majority of thyroid cancer samples compared to benign lesions (p < 0.05).
• Akt1 was predominantly localized in the cytoplasm in differentiated thyroid cancers and benign lesions.
• Anaplastic thyroid cancers showed predominantly nuclear localization of Akt1 in two out of three samples.
• The ratio of phosphorylated Akt1 to total Akt1 was lower in thyroid cancers than in non-neoplastic lesions and adenomas.

Conclusions:

• Akt1 is overexpressed in thyroid neoplasms.
• Despite overexpression, high Akt1 phosphorylation is not a characteristic feature of thyroid cancers.
• Akt1 localization may differ between benign and malignant thyroid tissues, particularly in anaplastic carcinomas.